首頁 > 市場調查報告書 > 醫療設備

體外診斷

MRD檢測市場規模、佔有率和成長分析：按技術、方法、適應症、最終用戶、銷售管道和地區分類－2026-2033年產業預測

市場調查報告書

商品編碼

2026512

MRD檢測市場規模、佔有率和成長分析：按技術、方法、適應症、最終用戶、銷售管道和地區分類－2026-2033年產業預測

MRD Testing Market Size, Share, and Growth Analysis, By Technology (Next-Generation Sequencing, Flow Cytometry), By Method, By Indication, By End-User, By Sales Channel, By Region - Industry Forecast 2026-2033

出版日期: 2026年04月06日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球 MRD 檢測市場價值為 21.4 億美元，預計到 2033 年將從 2025 年的 24.1 億美元成長至 63 億美元，預測期（2026-2033 年）的複合年成長率為 12.8%。

全球微量殘存疾病（MRD）檢測市場的發展動力源於對比傳統影像學方法更靈敏的殘留癌細胞檢測的迫切需求。 MRD檢測在預後評估、治療策略制定和療效監測中發揮至關重要的作用，因為它能夠早期識別復發的可能性，最終改善患者的治療效果。從傳統的流式細胞技術到數位PCR和次世代定序等先進技術的轉變，顯著提高了檢測的靈敏度和準確性。檢測結果可解讀性的提升有助於制定切實可行的臨床決策，從而進一步推動市場成長。人工智慧的整合透過最佳化循環腫瘤DNA的訊號提取和增強變異識別，顯著提高了檢測靈敏度。這項技術進步將促進MRD檢測在臨床實踐中的更廣泛應用，並為包括固態腫瘤和患者時間序列監測在內的MRD綜合應用鋪平道路。

全球微小殘留疾病檢測市場的成長要素

全球微量殘存疾病（MRD）檢測市場的成長主要得益於高靈敏度分子檢測技術的進步。這些技術顯著提高了對極低濃度殘留癌細胞的辨識能力。檢測靈敏度和特異性的提升增強了臨床信心，從而能夠做出更精準的治療決策，並有效監測治療進展和復發。因此，這些技術進步正在推動MRD檢測服務和平台在各種臨床環境中的應用。此外，這些進步也促進了診斷技術開發商和醫療服務提供者之間的合作，並推動了對這些關鍵檢測方法的引入和檢驗的投資。

全球微小殘留疾病檢測市場的限制因素

全球微量殘存疾病（MRD）檢測市場面臨許多限制因素，其中之一是先進檢測方法和所需設備的高成本。這些成本會阻礙MRD檢測的普及，尤其是在資源有限的醫院和檢查室，預算競爭更為激烈。這種經濟負擔會影響檢測實施、檢查室認證和專用設備採購等關鍵決策，常常導致小規模臨床中心無法提供MRD檢測服務。此外，成本問題還會使與保險公司的談判複雜化，並限制某些患者群體獲得檢測的機會。因此，這些經濟和營運方面的挑戰正在阻礙MRD檢測市場的整體成長和廣泛應用。

全球微小殘留疾病檢測市場趨勢

全球微量殘存疾病（MRD）檢測市場正呈現出顯著的人工智慧診斷融合趨勢，臨床檢查室和儀器製造商正優先考慮將機器學習和預測分析技術整合到其工作流程中。這項創新旨在提升訊號檢測能力並解讀複雜的分子特徵，從而實現更有效率、更一致的報告流程。透過減少主觀解讀，該技術促進了自適應檢測路徑的構建，以有效應對不斷變化的生物學模式。此外，這一趨勢還加強了診斷開發人員和軟體供應商之間的合作，從而加快了檢驗流程，提高了檢查室工作流程的一致性，最終將演算法輸出轉化為可操作的信息，有助於改進治療決策。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

Adaptive Biotechnologies
Natera
Guardant Health
Roche
Illumina
Thermo Fisher Scientific
Bio-Rad Laboratories
Invitae
Exact Sciences
Sysmex
Quest Diagnostics
Labcorp
NeoGenomics
ArcherDX
Qiagen
BGI Genomics
Myriad Genetics
Personalis
Invivoscribe
F. Hoffmann-La Roche

結論與建議

簡介目錄

Product Code: SQMIG35J2259

Global Mrd Testing Market size was valued at USD 2.14 Billion in 2024 and is poised to grow from USD 2.41 Billion in 2025 to USD 6.3 Billion by 2033, growing at a CAGR of 12.8% during the forecast period (2026-2033).

The global minimal residual disease (MRD) testing market is driven by the crucial need for highly sensitive detection of residual cancer cells, which surpasses traditional imaging methods. MRD testing plays a pivotal role in assessing prognosis, guiding treatment decisions, and monitoring therapeutic efficacy as it identifies relapse potential early, ultimately improving patient outcomes. Transitioning from conventional flow cytometry to advanced techniques like digital PCR and next-generation sequencing has significantly advanced sensitivity and precision. Enhanced assay interpretation fosters actionable clinical decisions, further stimulating market growth. The integration of AI significantly boosts sensitivity by refining signal extraction from circulating tumor DNA and enhancing variant calling. This technological evolution promotes broader clinical adoption and paves the way for comprehensive MRD applications, including solid tumors and longitudinal patient monitoring.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Mrd Testing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Mrd Testing Market Segments Analysis

Global mrd testing market is segmented by technology, method, indication, end-user, sales channel and region. Based on technology, the market is segmented into Next-Generation Sequencing, Flow Cytometry, Polymerase Chain Reaction and Others. Based on method, the market is segmented into Peripheral Blood Cell Testing, Methylation Sequencing Testing, High-Throughput Sequencing Testing and Others. Based on indication, the market is segmented into Hematological Malignancies, Solid Tumors and Others. Based on end-user, the market is segmented into Hospitals and Specialty Clinics, Diagnostic Laboratories, Research and Academic Institutes and Others. Based on sales channel, the market is segmented into Direct Sales, Medical Device Distributors, Online Healthcare Platforms and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Mrd Testing Market

The growth of the Global Minimal Residual Disease (MRD) Testing market is significantly propelled by advancements in high-sensitivity molecular detection technologies, which have improved the ability to identify residual cancer cells at much lower levels. This heightened sensitivity and specificity of assays enhances clinical confidence, enabling more accurate treatment decisions and effective monitoring of therapy and relapse. Consequently, this technological progress encourages a wider adoption of MRD testing services and platforms in various clinical environments. Additionally, it fosters collaboration between diagnostic developers and healthcare providers, while promoting investments for the implementation and validation of these critical tests.

Restraints in the Global Mrd Testing Market

The global Minimal Residual Disease (MRD) testing market faces significant constraints due to the high costs associated with advanced assays and the necessary instrumentation. These expenses can hinder the adoption of MRD testing among hospitals and laboratories, particularly those that prioritize competing budgetary demands and have limited resources. The financial burden influences critical decisions regarding test implementation, obtaining laboratory accreditation, and procuring specialized equipment, often preventing smaller clinical centers from providing MRD testing services. Additionally, cost-related issues can complicate discussions with payers, restricting access to testing for certain patient populations. As a result, these economic and operational challenges impede the overall growth and widespread acceptance of MRD testing in the market.

Market Trends of the Global Mrd Testing Market

The Global Minimal Residual Disease (MRD) Testing market is witnessing a prominent trend towards the integration of AI-driven diagnostics, as clinical laboratories and instrument manufacturers prioritize the incorporation of machine learning and predictive analytics into their workflows. This innovation aims to enhance signal detection and interpret complex molecular signatures, facilitating a more streamlined and consistent reporting process. The emphasis on reducing subjective interpretation fosters adaptive testing pathways to effectively respond to evolving biological patterns. Additionally, this trend promotes stronger collaboration between diagnostics developers and software vendors, leading to faster validation processes and greater alignment of laboratory workflows, ultimately translating algorithmic outputs into actionable information for improved treatment decisions.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape

Global MRD Testing Market Size by Technology & CAGR (2026-2033)

Market Overview
Next-Generation Sequencing
Flow Cytometry
Polymerase Chain Reaction
Others

Global MRD Testing Market Size by Method & CAGR (2026-2033)

Market Overview
Peripheral Blood Cell Testing
Methylation Sequencing Testing
High-Throughput Sequencing Testing
Others

Global MRD Testing Market Size by Indication & CAGR (2026-2033)

Market Overview
Hematological Malignancies
- Leukemia
- Lymphoma
- Multiple Myeloma
Solid Tumors
Others

Global MRD Testing Market Size by End-User & CAGR (2026-2033)

Market Overview
Hospitals and Specialty Clinics
Diagnostic Laboratories
Research and Academic Institutes
Others

Global MRD Testing Market Size by Sales Channel & CAGR (2026-2033)

Market Overview
Direct Sales
Medical Device Distributors
Online Healthcare Platforms
Others

Global MRD Testing Market Size & CAGR (2026-2033)

North America (Technology, Method, Indication, End-User, Sales Channel)
- US
- Canada
Europe (Technology, Method, Indication, End-User, Sales Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Technology, Method, Indication, End-User, Sales Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Technology, Method, Indication, End-User, Sales Channel)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Technology, Method, Indication, End-User, Sales Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Adaptive Biotechnologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Invitae
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exact Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quest Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Labcorp
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NeoGenomics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ArcherDX
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Qiagen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BGI Genomics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Personalis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Invivoscribe
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments